Celldex Therapeutics reported $721.53M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 96.05B 409M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Celldex Therapeutics USD 721.53M 60.82M Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Northwest Biotherapeutics USD 80.05M 49.44M Mar/2026
Pfizer USD 204.54B 3.41B Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026